Trial results showing improved overall survival with a combination of azacitidine and venetoclax may prompt a change how clinicians approach treatment in older adults newly diagnosed with acute myeloid leukaemia (AML). Results from the VIALE-A trial presented at the European Hematology Association virtual congress (EHA25) showed that the combination of azacitidine and venetoclax was associated ...
Venetoclax plus azacitidine may be new standard of care for older AML patients
By Emma Wilkinson
25 Jun 2020